Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions

Area of Science:

• Dermatology and Nanotechnology
• Advanced Therapeutics
• Bioengineering

Background:

• Psoriasis is a chronic inflammatory skin disease affecting 2-3% of the global population.
• Conventional therapies face challenges including poor drug penetration, systemic toxicity, and relapse.
• The unique pathophysiology of psoriatic skin hinders effective drug delivery.

Purpose of the Study:

• To review recent advancements in drug delivery systems for psoriasis therapy.
• To evaluate nanotechnology-driven platforms and bioengineered systems for improved therapeutic outcomes.
• To explore the potential of these advanced systems in personalized dermatology.

Main Methods:

• Review of emerging drug delivery systems and devices.
• Analysis of nanocarrier-based platforms, microneedle-assisted delivery, hydrogels, and nanofiber matrices.
• Evaluation of stimuli-responsive and bio-inspired systems, including plant-derived bioactives and extracellular vesicles.

Main Results:

• Nanocarrier platforms enhance drug localization, bioavailability, and inflammatory pathway modulation.
• Microneedles, hydrogels, and nanofibers provide localized, sustained, and patient-friendly administration.
• Stimuli-responsive and bio-inspired systems advance personalized and precision medicine in dermatology.

Conclusions:

• Advanced drug delivery systems show significant promise for overcoming limitations of conventional psoriasis treatments.
• These innovative platforms offer enhanced efficacy, targeted delivery, and improved patient compliance.
• The integration of these technologies could redefine the future of psoriasis management and clinical practice.